A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

Annals of Oncology

Volumn 7, Issue 10, 1996, Pages 1077-1079

  Swenerton, K ^a   Hoskins, P ^a   Stuart, G ^b   Batist, G ^c   Pike, J ^a   Onetto, N ^d   Fisher, B ^e   Eisenhauer, E ^e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d BRISTOL MYERS SQUIBB   (United States)

^e Institut national du cancer du Canada   (Canada)

Author keywords

Cisplatin; Ovarian cancer; Paclitaxel; Phase I study

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRANULOCYTOPENIA; HUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030466715     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010502     Document Type: Article

References (10)

1. Palmer MC, Shepert E, Schepansky A et al. Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer. Int J Gynecol Cancer 1992; 2: 301-6.
2. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
3. Einzig AI, Wiernik PH, Sasloff J et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-53.
4. Thigpen T, Blessing J, Ball H et al. Phase II trial of taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 1990; 9: 156 (Abstr 604).
5. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive for ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study. J Clin Oncol 1994; 12: 1748-53.
6. Eisenhauer E, ten Bokkel-Huinink W, Swenerton K et al. Toxicity of taxol: A European-Canadian trial of high- vs. low-dose and short vs. long infusion in ovarian cancer coordinated by the NCI Canada Clinical Trials Group. Second National Cancer Institute Workshop on Taxol and Taxus, Alexandra VA, Sept. 1992 (Abstr).
7. Rowinsky EK, Doneower RC. Taxol: Twenty years later, the story unfolds. J Natl Cancer Inst 1991; 83: 1778-81.
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian trial of paclitaxel in relapsed ovarian cancer: High- versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
9. Gelmon KA, O'Reilly SE, Tolcher AW et al. A phase I/II trial of bi-weekly paclitaxel (taxol) and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14: 1185-91.
10. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.